Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Macular Degeneration Doubles Heart Attack and Stroke Risk

By HospiMedica staff writers
Posted on 26 Mar 2008
Age related macular degeneration (AMD) doubles the risk of dying from a heart attack or a stroke, according to a new study.

Researchers at the University of Sydney (Australia) analyzed over 3654 baseline participants aged 49 years or more between 1992 and 1994. More...
Five years later, a follow up was performed on 2335 of these people, and after ten years, 1952 were examined again. History and physical examination provided data on possible risk factors, and the analysis included retinal photographs graded using the Wisconsin system. Deaths and cause of death were confirmed by data linkage with the Australian National Death Index. Risk ratios (RR) were estimated using Cox models.

The results showed that of the population under age 75 who participated in the study, early presentation of AMD predicted a doubling of cardiovascular mortality from heart attack or stroke within a decade. The late stage disease was associated with a five-fold increase in death from heart attack and ten time the risk of death from stroke. These associations were not present when persons older than 75 were included. The study was published in the February 28, 2008, issue of the British Journal of Ophthalmology.

"As there are some concerns that current treatments for AMD could elevate stroke risk, these results have extremely important implications for the treatment of this disease in the elderly,” concluded lead author Professor Paul Mitchell, M.D., and colleagues of the department of ophthalmology.

AMD is a degenerative condition of the macula, the central part of the retina, and is caused by hardening of the arteries in the retina, which deprives the sensitive retinal tissue of oxygen and nutrients that it needs to function and thrive. This can result in loss of central vision, which entails inability to see fine details, to read, or to recognize faces. Advanced AMD, which is responsible for profound vision loss, has two forms: dry and wet. Central geographic atrophy, the dry form of advanced AMD, results from atrophy to the retinal pigment epithelial layer below the retina, which causes vision loss through loss of photoreceptors (rods and cones) in the central part of the eye. Exudative AMD, the wet form of advanced AMD, causes vision loss due to abnormal blood vessel growth in the choriocapillaries, ultimately leading to blood and protein leakage below the macula, eventually causing irreversible damage to the photoreceptors and rapid vision loss if left untreated.


Related Links:
University of Sydney

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.